News | May 18, 2021
Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
India sales grew 23.5% YoY with consolidation of Wockhardt products
India sales grew 23.5% YoY with consolidation of Wockhardt products
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Subscribe To Our Newsletter & Stay Updated
